20/11/2023 - 13:33

Chimeric set to flick switch on clinical leukaemia trial

20/11/2023 - 13:33


Upgrade your subscription to use this feature.

Chimeric Therapeutics expects a phase-1B clinical trial into its “natural killer” cell therapy for newly-diagnosed patients with acute myeloid leukemia to be open for new enrolments before the end of the year. The study, which has received investigational new drug clearance from the USFDA, is designed to enrol up to 20 patients who are not eligible for intensive chemotherapy or allogeneic stem cell transplant.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options